ImmunoPrecise Antibodies Ltd. (HYFT)vsModerna Inc (MRNA)
HYFT
ImmunoPrecise Antibodies Ltd.
$1.20
+1.69%
HEALTHCARE · Cap: $56.53M
MRNA
Moderna Inc
$214.17
+2.98%
HEALTHCARE · Cap: $87.04B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 13627% more annual revenue ($2.23B vs $16.23M). HYFT leads profitability with a -105.2% profit margin vs -141.4%. HYFT earns a higher WallStSmart Score of 24/100 (F).
HYFT
Avoid24
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for HYFT.
Margin of Safety
+69.9%
Fair Value
$134.71
Current Price
$214.16
$79.45 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 21.3% year-over-year
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
Trading at 12.0x book value
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -81.3% — below average capital efficiency
Trading at 12.6x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : HYFT
The strongest argument for HYFT centers on Revenue Growth. Revenue growth of 21.3% demonstrates continued momentum.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : HYFT
The primary concerns for HYFT are Price/Book, EPS Growth, Market Cap.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
HYFT profiles as a growth stock while MRNA is a turnaround play — different risk/reward profiles.
MRNA carries more volatility with a beta of 1.09 — expect wider price swings.
HYFT is growing revenue faster at 21.3% — sustainability is the question.
HYFT generates stronger free cash flow (-4M), providing more financial flexibility.
Bottom Line
HYFT scores higher overall (24/100 vs 21/100) and 21.3% revenue growth. MRNA offers better value entry with a 69.9% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
ImmunoPrecise Antibodies Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
MindWalk Holdings Corp. The company is headquartered in Austin, Texas.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?